Acute Myeloid Leukemia
Cross-source consensus on Acute Myeloid Leukemia from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Risks & contraindications
Evidence quality
Other
Highlighted claims
- Most treated patients had AML rather than MDS. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- The trial enrolled adults with CD33+ AML or MDS at high relapse risk after HLA-matched allogeneic transplantation. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- The trial was not designed to establish definitive relapse-prevention efficacy in AML or MDS. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- Allogeneic hematopoietic cell transplantation is standard care for AML patients unlikely to be cured with chemotherapy alone. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- Relapse after transplant remains common in high-risk AML, especially with adverse genetics, measurable residual disease, or secondary AML. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- All relapses in the study remained CD33-positive, suggesting relapse was not driven by CD33 antigen loss. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial